Allogeneic chimeric antigen receptor-T cells with CRISPR-disrupted programmed death-1 checkpoint exhibit enhanced functional fitness.

Autor: Lau E; Caribou Biosciences, Inc., Berkeley, California, USA., Kwong G; Caribou Biosciences, Inc., Berkeley, California, USA., Fowler TW; Caribou Biosciences, Inc., Berkeley, California, USA., Sun BC; Caribou Biosciences, Inc., Berkeley, California, USA., Donohoue PD; Caribou Biosciences, Inc., Berkeley, California, USA., Davis RT; Caribou Biosciences, Inc., Berkeley, California, USA., Bryan M; Caribou Biosciences, Inc., Berkeley, California, USA., McCawley S; Caribou Biosciences, Inc., Berkeley, California, USA., Clarke SC; Caribou Biosciences, Inc., Berkeley, California, USA., Williams C; Caribou Biosciences, Inc., Berkeley, California, USA., Banh L; Caribou Biosciences, Inc., Berkeley, California, USA., Irby M; Caribou Biosciences, Inc., Berkeley, California, USA., Edwards L; Caribou Biosciences, Inc., Berkeley, California, USA., Storlie M; Caribou Biosciences, Inc., Berkeley, California, USA., Kohrs B; Caribou Biosciences, Inc., Berkeley, California, USA., Lilley GWJ; Caribou Biosciences, Inc., Berkeley, California, USA., Smith SC; Caribou Biosciences, Inc., Berkeley, California, USA., Gradia S; Caribou Biosciences, Inc., Berkeley, California, USA., Fuller CK; Caribou Biosciences, Inc., Berkeley, California, USA., Skoble J; Caribou Biosciences, Inc., Berkeley, California, USA., Garner E; Caribou Biosciences, Inc., Berkeley, California, USA., van Overbeek M; Caribou Biosciences, Inc., Berkeley, California, USA., Kanner SB; Caribou Biosciences, Inc., Berkeley, California, USA. Electronic address: skanner@cariboubio.com.
Jazyk: angličtina
Zdroj: Cytotherapy [Cytotherapy] 2023 Jul; Vol. 25 (7), pp. 750-762. Date of Electronic Publication: 2023 Apr 21.
DOI: 10.1016/j.jcyt.2023.03.011
Abstrakt: Background Aims: Therapeutic disruption of immune checkpoints has significantly advanced the armamentarium of approaches for treating cancer. The prominent role of the programmed death-1 (PD-1)/programmed death ligand-1 axis for downregulating T cell function offers a tractable strategy for enhancing the disease-modifying impact of CAR-T cell therapy.
Methods: To address checkpoint interference, primary human T cells were genome edited with a next-generation CRISPR-based platform (Cas9 chRDNA) by knockout of the PDCD1 gene encoding the PD-1 receptor. Site-specific insertion of a chimeric antigen receptor specific for CD19 into the T cell receptor alpha constant locus was implemented to drive cytotoxic activity.
Results: These allogeneic CAR-T cells (CB-010) promoted longer survival of mice in a well-established orthotopic tumor xenograft model of a B cell malignancy compared with identically engineered CAR-T cells without a PDCD1 knockout. The persistence kinetics of CB-010 cells in hematologic tissues versus CAR-T cells without PDCD1 disruption were similar, suggesting the robust initial debulking of established tumor xenografts was due to enhanced functional fitness. By single-cell RNA-Seq analyses, CB-010 cells, when compared with identically engineered CAR-T cells without a PDCD1 knockout, exhibited fewer T reg cells, lower exhaustion phenotypes and reduced dysfunction signatures and had higher activation, glycolytic and oxidative phosphorylation signatures. Further, an enhancement of mitochondrial metabolic fitness was observed, including increased respiratory capacity, a hallmark of less differentiated T cells.
Conclusions: Genomic PD-1 checkpoint disruption in the context of allogeneic CAR-T cell therapy may provide a compelling option for treating B lymphoid malignancies.
Competing Interests: Declaration of Competing Interest All authors are current or former employees of Caribou Biosciences, Inc.
(Copyright © 2023 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: